| Year |
Citation |
Score |
| 2020 |
Gindin Y, Chung C, Jiang Z, Zhou JZ, Xu J, Billin A, Myers RP, Goodman Z, Landi A, Houghton M, Green RM, Levy C, Kowdley KV, Bowlus CL, Muir AJ, et al. A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Novel Drivers of Disease Progression in Primary Sclerosing Cholangitis. Hepatology (Baltimore, Md.). PMID 32745270 DOI: 10.1002/Hep.31488 |
0.346 |
|
| 2020 |
Trivedi PJ, Muir AJ, Levy C, Bowlus CL, Manns M, Lu X, Crans G, Chung C, Subramanian GM, Myers RP, Goodman Z, Chalasani N, Vierling JM, Guha IN, Hirschfield GM. Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 32707342 DOI: 10.1016/J.Cgh.2020.07.032 |
0.344 |
|
| 2020 |
Zhou X, Kailemia MJ, Sun Y, Shuai Z, Yang GX, Dhaliwal S, Cristoferi L, Leung PSC, Invernizzi P, Bowlus CL, Lebrilla CB, Ansari AA, Ridgway WM, Zhang W, Gershwin ME. Glycomic analysis of antibody indicates distinctive glycosylation profile in patients with autoimmune cholangitis. Journal of Autoimmunity. 102503. PMID 32546343 DOI: 10.1016/J.Jaut.2020.102503 |
0.343 |
|
| 2020 |
Kowdley KV, Vuppalanchi R, Levy C, Floreani A, Andreone P, LaRusso NF, Shrestha R, Trotter J, Goldberg D, Rushbrook S, Hirschfield GM, Schiano T, Jin Y, Pencek R, MacConell L, ... ... Bowlus CL, et al. A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis. Journal of Hepatology. PMID 32165251 DOI: 10.1016/J.Jhep.2020.02.033 |
0.349 |
|
| 2020 |
Chang C, Tanaka A, Bowlus C, Gershwin ME. The use of biologics in the treatment of autoimmune liver disease. Expert Opinion On Investigational Drugs. 1-14. PMID 32102572 DOI: 10.1080/13543784.2020.1733527 |
0.391 |
|
| 2020 |
Hedin CRH, Sado G, Ndegwa N, Lytvyak E, Mason A, Montano-Loza A, Gerussi A, Saffioti F, Thorburn D, Nilsson E, Larsson G, Moum BA, van Munster KN, Ponsioen CY, Levy C, ... ... Bowlus CL, et al. Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 32068151 DOI: 10.1016/J.Cgh.2020.02.014 |
0.31 |
|
| 2020 |
Gordon SC, Wu KH, Lindor K, Bowlus CL, Rodriguez CV, Anderson H, Boscarino JA, Trudeau S, Rupp LB, Haller IV, Romanelli RJ, VanWormer JJ, Schmidt MA, Daida YG, Sahota A, et al. Ursodeoxycholic Acid Treatment Preferentially Improves Overall Survival Among African Americans With Primary Biliary Cholangitis. The American Journal of Gastroenterology. PMID 31985529 DOI: 10.14309/Ajg.0000000000000512 |
0.358 |
|
| 2019 |
Malik A, Kardashian AA, Zakharia K, Bowlus CL, Tabibian JH. Preventative care in cholestatic liver disease: Pearls for the specialist and subspecialist. Liver Research. 3: 118-127. PMID 32042471 DOI: 10.1016/J.Livres.2019.04.001 |
0.354 |
|
| 2019 |
Gao L, Wang L, Woo E, He X, Yang G, Bowlus C, Leung PSC, Gershwin ME. Clinical Management of Primary Biliary Cholangitis-Strategies and Evolving Trends. Clinical Reviews in Allergy & Immunology. PMID 31713023 DOI: 10.1007/S12016-019-08772-7 |
0.363 |
|
| 2019 |
Wang T, Liu Y, Letran D, Dang JHT, Harris AM, Li CS, Chen MS, Bowlus CL, Chak E. Healthcare Disparities Identified Between Hmong and Other Asian Origin Groups Living with Chronic Hepatitis B Infection in Sacramento County 2014-2017. Journal of Community Health. PMID 31612369 DOI: 10.1007/S10900-019-00763-1 |
0.304 |
|
| 2019 |
Bowlus CL, Pockros PJ, Kremer AE, Parés A, Forman LM, Drenth JPH, Ryder SD, Terracciano L, Jin Y, Liberman A, Pencek R, Iloeje U, MacConell L, Bedossa P. Long-term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 31606455 DOI: 10.1016/J.Cgh.2019.09.050 |
0.371 |
|
| 2019 |
Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D, Vierling JM, Adams D, Alpini G, Banales JM, Beuers U, Björnsson E, Bowlus C, Carbone M, Chazouillères O, Dalekos G, De Gottardi A, Harada K, et al. The challenges of primary biliary cholangitis: What is new and what needs to be done. Journal of Autoimmunity. 102328. PMID 31548157 DOI: 10.1016/J.Jaut.2019.102328 |
0.39 |
|
| 2019 |
Song J, Li Y, Bowlus CL, Yang G, Leung PSC, Gershwin ME. Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis (PSC): a Comprehensive Review. Clinical Reviews in Allergy & Immunology. PMID 31463807 DOI: 10.1007/S12016-019-08764-7 |
0.349 |
|
| 2019 |
Lynch KD, Chapman RW, Keshav S, Montano-Loza AJ, Mason AL, Kremer AE, Vetter M, de Krijger M, Ponsioen CY, Trivedi P, Hirschfield G, Schramm C, Liu CH, Bowlus CL, Estes DJ, et al. Effects of Vedolizumab in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 31100458 DOI: 10.1016/J.Cgh.2019.05.013 |
0.345 |
|
| 2019 |
Bowlus CL, Yang GX, Liu CH, Johnson CR, Dhaliwal SS, Frank D, Levy C, Peters MG, Vierling JM, Gershwin ME. Therapeutic trials of biologics in primary biliary cholangitis: An open label study of abatacept and review of the literature. Journal of Autoimmunity. PMID 31027870 DOI: 10.1016/J.Jaut.2019.04.005 |
0.343 |
|
| 2019 |
Mordaunt CE, Kieffer DA, Shibata NM, Członkowska A, Litwin T, Weiss KH, Zhu Y, Bowlus CL, Sarkar S, Cooper S, Wan YY, Ali MR, LaSalle JM, Medici V. Epigenomic signatures in liver and blood of Wilson disease patients include hypermethylation of liver-specific enhancers. Epigenetics & Chromatin. 12: 10. PMID 30709419 DOI: 10.1186/S13072-019-0255-Z |
0.345 |
|
| 2019 |
Trauner M, Gulamhusein A, Hameed B, Caldwell S, Shiffman ML, Landis C, Eksteen B, Agarwal K, Muir A, Rushbrook S, Lu X, Xu J, Chuang JC, Billin AN, Chung C, ... ... Bowlus CL, et al. The nonsteroidal FXR agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with PSC. Hepatology (Baltimore, Md.). PMID 30661255 DOI: 10.1002/Hep.30509 |
0.32 |
|
| 2019 |
Hirschfield GM, Nevens F, Shiffman ML, Drenth JP, Bowlus CL, Vargas V, Andreone P, Ryder S, Liberman A, Malecha ES, MacConell L, Trauner M. PTU-009 Long-term effects of obeticholic acid in patients with primary biliary cholangitis on inflammatory markers Gut. 68. DOI: 10.1136/Gutjnl-2019-Bsgabstracts.218 |
0.359 |
|
| 2019 |
Kremer AE, Bowlus CL, Bedossa P, Parés A, Forman LM, Drenth JP, Ryder S, Terracciano L, Jin Y, Liberman A, Pencek R, MacConell L, Pockros PJ. ATU-09 Obeticholic acid treatment is associated with improved collagen morphometry in patients with primary biliary cholangitis Gut. 68. DOI: 10.1136/Gutjnl-2019-Bsgabstracts.209 |
0.335 |
|
| 2019 |
Bowlus C, Pockros P, Kremer A, Pares A, Forman L, Drenth J, Ryder S, Floreani A, Terracciano L, Jin Y, Lieberman A, Pencheck R, Iloeje U, Macconell L, Bedossa P. OC.01.4 THREE YEARS OF OBETICHOLIC ACID (OCA) THERAPY RESULTS IN HISTOLOGICAL IMPROVEMENTS IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS: FURTHER ANALYSIS OF THE POISE BIOPSY SUBSTUDY Digestive and Liver Disease. 51: e78. DOI: 10.1016/S1590-8658(19)30138-0 |
0.304 |
|
| 2019 |
Mayo MJ, Bowlus C, Carey E, Little E, Deane K, Zink R, Sandefur R, Kim WR, Levy C. FRI-043-Primary biliary cholangitis-Autoimmune hepatitis overlap syndrome: Characteristics and response to obeticholic acid in TARGET-PBC, a diverse, large United States real-world cohort Journal of Hepatology. 70: e403. DOI: 10.1016/S0618-8278(19)30793-5 |
0.302 |
|
| 2019 |
Bowlus C, Shiffman M, Janssen H, Montano-Loza AJ, Caldwell S, Luketic V, Lu X, Crans G, Chung C, Subramanian M, Myers R, Manns MP, Levy C, Trauner M, Goodman Z, et al. PS-012-Validation of histologic and non-invasive measures of fibrosis as surrogate end points of disease progression in patients with primary sclerosing cholangitis Journal of Hepatology. 70: e10-e11. DOI: 10.1016/S0618-8278(19)30018-0 |
0.316 |
|
| 2019 |
Mayo MJ, Bowlus CL, Carey EJ, Little EC, Deane K, Zink RC, Sandefur R, Kim WR, Levy C. Tu1531 – Primary Biliary Cholangitis (PBC)-Autoimmune Hepatitis (AIH) Overlap Syndrome: Characteristics and Response to Obeticholic Acid (OCA) in Target-PBC, a Diverse, Large United States (US) Real-World Cohort Gastroenterology. 156: S-1355. DOI: 10.1016/S0016-5085(19)40411-3 |
0.305 |
|
| 2018 |
Floreani A, Restrepo-Jiménez P, Secchi MF, De Martin S, Leung PSC, Krawitt E, Bowlus CL, Gershwin ME, Anaya JM. Etiopathogenesis of autoimmune hepatitis. Journal of Autoimmunity. PMID 30385083 DOI: 10.1016/J.Jaut.2018.10.020 |
0.382 |
|
| 2018 |
Wong KA, Bahar R, Liu CH, Bowlus CL. Current Treatment Options for Primary Biliary Cholangitis. Clinics in Liver Disease. 22: 481-500. PMID 30259848 DOI: 10.1016/J.Cld.2018.03.003 |
0.364 |
|
| 2018 |
Muir AJ, Levy C, Janssen HLA, Montano-Loza AJ, Shiffman ML, Caldwell S, Luketic V, Ding D, Jia C, McColgan BJ, McHutchison JG, Subramanian GM, Myers RP, Manns M, Chapman R, ... ... Bowlus CL, et al. Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease. Hepatology (Baltimore, Md.). PMID 30153359 DOI: 10.1002/Hep.30237 |
0.337 |
|
| 2018 |
Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology (Baltimore, Md.). PMID 30070375 DOI: 10.1002/Cld.874 |
0.309 |
|
| 2018 |
Kuo A, Gomel R, Safer R, Lindor KD, Everson GT, Bowlus CL. Characteristics and Outcomes Reported by Patients With Primary Sclerosing Cholangitis Through an Online Registry. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 29705262 DOI: 10.1016/J.Cgh.2018.04.047 |
0.354 |
|
| 2018 |
Levy C, Shiffman M, Janssen H, Montano-Loza A, Caldwell S, Luketic V, Ding D, Mccolgan B, Myers R, Eksteen B, Chapman R, Manns M, Goodman Z, Bowlus C, Muir A, et al. Prospective evaluation of serum gamma-glutamyl transferase (GGT) for the prediction of disease progression in a randomized trial of patients with primary sclerosing cholangitis (PSC) Journal of Hepatology. 68: S568. DOI: 10.1016/S0168-8278(18)31394-1 |
0.323 |
|
| 2018 |
Boudes P, Michael G, Bowlus C, Hirschfield G, Jones D, Odin J, Sheridan D, Gitlin N, Harrison S, Hassanein T, Levy C, Shiffman M, Thorburn D, Thuluvath P, Vierling J, et al. Pharmacokinetics and pharmacodynamics of seladelpar, a potent and selective PPAR-delta, in patients with primary biliary cholangitis Journal of Hepatology. 68: S235. DOI: 10.1016/S0168-8278(18)30687-1 |
0.301 |
|
| 2018 |
Bowlus C, Pockros P, Kremer A, Pares A, Forman L, Drenth J, Ryder S, Malecha E, Pencek R, Iloeje U, Macconell L, Shapiro D, Pierre B. Long-Term Obeticholic Acid (OCA) treatment associated with reversal or stabilization of fibrosis/cirrhosis in patients with Primary Biliary Cholangitis (PBC) Journal of Hepatology. 68: S111-S112. DOI: 10.1016/S0168-8278(18)30441-0 |
0.316 |
|
| 2018 |
Chew M, Bowlus CL. Primary biliary cholangitis: Diagnosis and treatment Liver Research. 2: 81-86. DOI: 10.1016/J.Livres.2018.03.004 |
0.34 |
|
| 2017 |
Tabibian JH, Bowlus CL. Primary sclerosing cholangitis: A review and update. Liver Research. 1: 221-230. PMID 29977644 DOI: 10.1016/J.Livres.2017.12.002 |
0.372 |
|
| 2017 |
Lu M, Zhou Y, Haller IV, Romanelli RJ, VanWormer JJ, Rodriguez CV, Anderson H, Boscarino JA, Schmidt MA, Daida YG, Sahota A, Vincent J, Bowlus CL, Lindor K, Zhang T, et al. Increasing Prevalence of Primary Biliary Cholangitis and Reduced Mortality with Treatment. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 29277621 DOI: 10.1016/J.Cgh.2017.12.033 |
0.326 |
|
| 2017 |
Yao M, Wang L, Leung PSC, Li Y, Liu S, Wang L, Guo X, Zhou G, Yan Y, Guan G, Chen X, Bowlus CL, Liu T, Jia J, Gershwin ME, et al. The Clinical Significance of GP73 in Immunologically Mediated Chronic Liver Diseases: Experimental Data and Literature Review. Clinical Reviews in Allergy & Immunology. PMID 29256057 DOI: 10.1007/S12016-017-8655-Y |
0.335 |
|
| 2017 |
Younossi ZM, Afendy A, Stepanova M, Racila A, Nader F, Gomel R, Safer R, Lenderking WR, Skalicky A, Kleinman L, Myers RP, Subramanian GM, McHutchison JG, Levy C, Bowlus CL, et al. Development and Validation of a Primary Sclerosing Cholangitis-Specific Patient-Reported Outcomes Instrument: The PSC PRO. Hepatology (Baltimore, Md.). PMID 29152767 DOI: 10.1002/Hep.29664 |
0.33 |
|
| 2017 |
Goldberg D, Levy C, Yimam K, Gordon S, Forman L, Verna E, Yu L, Rahimi R, Schwarz K, Eksteen B, Pratt D, Boyer T, Assis D, Bowlus C. Primary Sclerosing Cholangitis is not Rare Among Blacks in a Multi-Center North American Consortium. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 29102704 DOI: 10.1016/J.Cgh.2017.10.028 |
0.353 |
|
| 2017 |
Jones D, Boudes PF, Swain MG, Bowlus CL, Galambos MR, Bacon BR, Doerffel Y, Gitlin N, Gordon SC, Odin JA, Sheridan D, Wörns MA, Clark V, Corless L, Hartmann H, et al. Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study. The Lancet. Gastroenterology & Hepatology. PMID 28818518 DOI: 10.1016/S2468-1253(17)30246-7 |
0.316 |
|
| 2017 |
Song J, Lleo A, Yang GX, Zhang W, Bowlus CL, Eric Gershwin M, Leung PSC. Common Variable Immunodeficiency and Liver Involvement. Clinical Reviews in Allergy & Immunology. PMID 28785926 DOI: 10.1007/S12016-017-8638-Z |
0.402 |
|
| 2017 |
Alberts R, de Vries EMG, Goode EC, Jiang X, Sampaziotis F, Rombouts K, Böttcher K, Folseraas T, Weismüller TJ, Mason AL, Wang W, Alexander G, Alvaro D, Bergquist A, Björkström NK, ... ... Bowlus CL, et al. Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. Gut. PMID 28779025 DOI: 10.1136/Gutjnl-2016-313598 |
0.325 |
|
| 2017 |
Floreani A, Tanaka A, Bowlus C, Gershwin ME. Geoepidemiology and changing mortality in primary biliary cholangitis. Journal of Gastroenterology. PMID 28365879 DOI: 10.1007/S00535-017-1333-2 |
0.37 |
|
| 2017 |
Chang C, Lleo A, Kananurak A, Grizzi F, Tsuneyama K, Invernizzi P, Bevins CL, Bowlus CL. Human β-Defensin 2 in Primary Sclerosing Cholangitis. Clinical and Translational Gastroenterology. 8: e80. PMID 28300822 DOI: 10.1038/Ctg.2017.8 |
0.345 |
|
| 2017 |
Weismüller TJ, Trivedi PJ, Bergquist A, Imam M, Lenzen H, Ponsioen CY, Holm K, Gotthardt D, Färkkilä MA, Marschall HU, Thorburn D, Weersma RK, Fevery J, Mueller T, Chaouillères O, ... ... Bowlus CL, et al. Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. Gastroenterology. PMID 28274849 DOI: 10.1053/J.Gastro.2017.02.038 |
0.328 |
|
| 2017 |
Levy C, Eksteen B, Shiffman M, Janssen H, Montano-Loza A, Ding D, Jia C, Mccolgan B, Myers R, Subramanian M, McHutchison J, Chapman R, Manns M, Goodman Z, Bowlus C, et al. Prospective validation of serum alkaline phosphatase for the prediction of disease progression in a randomized trial of patients with primary sclerosing cholangitis Journal of Hepatology. 66: S360-S361. DOI: 10.1016/S0168-8278(17)31060-7 |
0.318 |
|
| 2017 |
Bowlus C, Patel K, Hirschfield G, Guha I, Chapman R, Chazouilleres O, Ding D, Jia C, Mccolgan B, Myers R, Subramanian M, McHutchison J, Muir A, Goodman Z, Rosenberg W, et al. Prospective validation of the Enhanced Liver Fibrosis test for the prediction of disease progression in a randomized trial of patients with primary sclerosing cholangitis Journal of Hepatology. 66: S359. DOI: 10.1016/S0168-8278(17)31056-5 |
0.354 |
|
| 2017 |
Hirschfield G, Galambos M, Bowlus C, Swain M, Doerffel Y, Steinberg A, Varga M, Choi Y, Martin R, Chera H, McWherter C, Boudes P, Jones D. Proof of efficacy for Seladelpar, a selective PPAR-δ agonist, in patients with primary biliary cholangitis non-responsive to ursodeoxycholic acid: results of an international Phase 2 randomised controlled clinical study Journal of Hepatology. 66: S357. DOI: 10.1016/S0168-8278(17)31052-8 |
0.313 |
|
| 2017 |
Shea P, Hirschfield G, Shiffman M, McColgan B, Goodman Z, Myers R, Subramanian M, Eksteen B, Janssen H, Bowlus C, Muir A, Montano-Loza A, McHutchison J, Manns M, Chapman R, et al. Common variation near glial-derived neurotrophic factor is associated with progression of hepatic collagen content in a genome-wide association study of liver fibrosis phenotypes in patients with primary sclerosing cholangitis Journal of Hepatology. 66: S4-S5. DOI: 10.1016/S0168-8278(17)30271-4 |
0.343 |
|
| 2017 |
Bowlus CL, Patel K, Hirschfield G, Guha N, Chapman RW, Chazouillères O, Ding D, Jia C, McColgan BJ, Natha M, Myers RP, Subramanian M, McHutchison J, Muir AJ, Goodman Z, et al. Prospective Validation of the Enhanced Liver Fibrosis (ELF) Test for the Prediction of Disease Progression in a Randomized Trial of Patients with Primary Sclerosing Cholangitis (PSC) Gastroenterology. 152: S1060. DOI: 10.1016/S0016-5085(17)33580-1 |
0.354 |
|
| 2016 |
Takakura WR, Tabibian JH, Bowlus CL. The evolution of natural history of primary sclerosing cholangitis. Current Opinion in Gastroenterology. PMID 28030370 DOI: 10.1097/Mog.0000000000000333 |
0.302 |
|
| 2016 |
Ji SG, Juran BD, Mucha S, Folseraas T, Jostins L, Melum E, Kumasaka N, Atkinson EJ, Schlicht EM, Liu JZ, Shah T, Gutierrez-Achury J, Boberg KM, Bergquist A, Vermeire S, ... ... Bowlus CL, et al. Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. Nature Genetics. PMID 27992413 DOI: 10.1038/Ng.3745 |
0.312 |
|
| 2016 |
Bowlus CL, Kenney JT, Rice G, Navarro R. Primary Biliary Cholangitis: Medical and Specialty Pharmacy Management Update. Journal of Managed Care & Specialty Pharmacy. 22: S3-S15. PMID 27700211 DOI: 10.18553/Jmcp.2016.22.10-A-S.S3 |
0.367 |
|
| 2016 |
Bowlus CL. Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection. Hepatic Medicine : Evidence and Research. 8: 89-95. PMID 27621676 DOI: 10.2147/Hmer.S91709 |
0.388 |
|
| 2016 |
Wang Z, Sheng L, Yang Y, Yang F, Xiao X, Hua J, Guo C, Wei Y, Tang R, Miao Q, Zhang J, Li Y, Fang J, Qiu D, Krawitt EL, ... Bowlus CL, et al. The Management of Autoimmune Hepatitis Patients with Decompensated Cirrhosis: Real-World Experience and a Comprehensive Review. Clinical Reviews in Allergy & Immunology. PMID 27515672 DOI: 10.1007/S12016-016-8583-2 |
0.323 |
|
| 2016 |
Sun Y, Zhang W, Evans JF, Floreani A, Zou Z, Nishio Y, Qi R, Leung PS, Bowlus CL, Gershwin ME. Autotaxin, Pruritus and Primary Biliary Cholangitis (PBC). Autoimmunity Reviews. PMID 27019050 DOI: 10.1016/J.Autrev.2016.03.019 |
0.347 |
|
| 2016 |
Sarkar S, Bowlus CL. Primary Sclerosing Cholangitis: Multiple Phenotypes, Multiple Approaches. Clinics in Liver Disease. 20: 67-77. PMID 26593291 DOI: 10.1016/J.Cld.2015.08.005 |
0.345 |
|
| 2016 |
Goodman Z, Patel K, Guha I, Hameed B, Kowdley K, Alaparthi L, Monge F, Myers R, Aguilar R, Subramanian G, McHutchison J, Bowlus C, Levy C, Manns M, Chapman R, et al. Correlations between Hepatic Morphometric Collagen Content, Histologic Fibrosis Stage, and Serum Markers in Patients with Primary Sclerosing Cholangitis (PSC) Journal of Hepatology. 64: S652-S653. DOI: 10.1016/S0168-8278(16)01221-6 |
0.317 |
|
| 2016 |
Alberts R, de Vries E, Alexander G, Alvaro D, Bergquist A, Beuers U, Björnsson E, Boberg K, Bowlus C, Chapman R, Chazouilléres O, Cheung A, Dalekos G, Eksteen B, Eaton J, et al. Genotype-Phenotype Analysis across 130,422 Genetic Variants Identifies Rspo3 as the First Genome-Wide Significant Modifier Gene in Primary Sclerosing Cholangitis Journal of Hepatology. 64: S642-S643. DOI: 10.1016/S0168-8278(16)01197-1 |
0.301 |
|
| 2016 |
Bowlus C, Montano-Loza A, Invernizzi P, Chazouillères O, Hirschfield G, Metselaar H, Goodman Z, Myers R, Aguilar R, Mani Subramanian G, McHutchison J, Chapman R, Muir A, Eksteen B, Levy C. Liver Stiffness Measurement by Transient Elastography for the Prediction of Fibrosis in Patients with Primary Sclerosing Cholangitis in a Randomized Trial of Simtuzumab Journal of Hepatology. 64: S434. DOI: 10.1016/S0168-8278(16)00710-8 |
0.331 |
|
| 2016 |
Muir A, Goodman Z, Bowlus C, Caldwell S, Invernizzi P, Luketic V, Minuk G, Hirschfield G, Myers R, Ding D, Aguilar R, Subramanian G, McHutchison J, Eksteen B, Levy C. Serum LYSYL Oxidase-Like-2 (SLOXL2) Levels Correlate with Disease Severity in Patients with Primary Sclerosing Cholangitis Journal of Hepatology. 64: S428. DOI: 10.1016/S0168-8278(16)00694-2 |
0.311 |
|
| 2016 |
Shea P, Eksteen B, Hirschfield G, Shiftman M, Janssen H, Montano-Loza A, Goodman Z, Kleinstein S, Myers R, Subramanian G, McHutchison J, Bowlus C, Manns M, Chapman R, Levy C, et al. Genome-Wide Association Study (Gwas) of Liver Fibrosis Phenotypes in Patients with Primary Sclerosing Cholangitis (Psc) Reveals Common Genetic Variation Influencing Serum Levels of Lysyl Oxidase-Like-2 (Loxl2) Journal of Hepatology. 64: S180-S181. DOI: 10.1016/S0168-8278(16)00112-4 |
0.332 |
|
| 2016 |
Yimam KK, Eksteen B, Wei EK, Kuo A, Corwin M, Kagay CR, Chou C, Bowlus C. Sa1573 Liver Stiffness (LS) Measured by Magnetic Resonance Elastography (MRE) is a Better Predictor of Hepatic Decompensation or Liver transplantation (LT) in Patients With Primary Sclerosing Cholangitis (PSC) than Model for End-Stage Liver Disease (MELD) Score or PSC Mayo Risk Score (MRS) Gastroenterology. 150. DOI: 10.1016/S0016-5085(16)33616-2 |
0.323 |
|
| 2016 |
Bowlus CL. Primary Sclerosing Cholangitis Clinics in Liver Disease. 20: 233-242. DOI: 10.1016/B978-0-323-47874-8.00017-1 |
0.385 |
|
| 2015 |
Floreani A, Sun Y, Zou ZS, Li B, Cazzagon N, Bowlus CL, Gershwin ME. Proposed therapies in primary biliary cholangitis. Expert Review of Gastroenterology & Hepatology. PMID 26577047 DOI: 10.1586/17474124.2016.1121810 |
0.352 |
|
| 2015 |
Tomiyama T, Yang GX, Zhao M, Zhang W, Tanaka H, Wang J, Leung PS, Okazaki K, He XS, Lu Q, Coppel RL, Bowlus CL, Gershwin ME. The modulation of co-stimulatory molecules by circulating exosomes in primary biliary cirrhosis. Cellular & Molecular Immunology. PMID 26388238 DOI: 10.1038/Cmi.2015.86 |
0.352 |
|
| 2015 |
Tanaka H, Yang GX, Tomiyama T, Tsuneyama K, Zhang W, Leung PS, Coppel RL, Joh T, Nadler SG, Ansari AA, Bowlus C, Gershwin ME. Immunological potential of cytotoxic T lymphocyte antigen 4 immunoglobulin in murine autoimmune cholangitis. Clinical and Experimental Immunology. 180: 371-82. PMID 25581259 DOI: 10.1111/Cei.12581 |
0.344 |
|
| 2015 |
Mousa HS, Lleo A, Invernizzi P, Bowlus CL, Gershwin ME. Advances in pharmacotherapy for primary biliary cirrhosis. Expert Opinion On Pharmacotherapy. 16: 633-43. PMID 25543678 DOI: 10.1517/14656566.2015.998650 |
0.374 |
|
| 2015 |
Floreani A, Franceschet I, Perini L, Cazzagon N, Gershwin ME, Bowlus CL. New therapies for primary biliary cirrhosis. Clinical Reviews in Allergy & Immunology. 48: 263-72. PMID 25331740 DOI: 10.1007/S12016-014-8456-5 |
0.36 |
|
| 2015 |
Norman GL, Yang CY, Ostendorff HP, Shums Z, Lim MJ, Wang J, Awad A, Hirschfield GM, Milkiewicz P, Bloch DB, Rothschild KJ, Bowlus CL, Adamopoulos IE, Leung PS, Janssen HJ, et al. Anti-kelch-like 12 and anti-hexokinase 1: novel autoantibodies in primary biliary cirrhosis. Liver International : Official Journal of the International Association For the Study of the Liver. 35: 642-51. PMID 25243383 DOI: 10.1111/Liv.12690 |
0.333 |
|
| 2014 |
Zhang J, Zhang W, Leung PS, Bowlus CL, Dhaliwal S, Coppel RL, Ansari AA, Yang GX, Wang J, Kenny TP, He XS, Mackay IR, Gershwin ME. Ongoing activation of autoantigen-specific B cells in primary biliary cirrhosis. Hepatology (Baltimore, Md.). 60: 1708-16. PMID 25043065 DOI: 10.1002/Hep.27313 |
0.31 |
|
| 2014 |
Yimam KK, Bowlus CL. Diagnosis and classification of primary sclerosing cholangitis. Autoimmunity Reviews. 13: 445-50. PMID 24424180 DOI: 10.1016/J.Autrev.2014.01.040 |
0.371 |
|
| 2014 |
Bowlus CL, Gershwin ME. The diagnosis of primary biliary cirrhosis. Autoimmunity Reviews. 13: 441-4. PMID 24424173 DOI: 10.1016/J.Autrev.2014.01.041 |
0.382 |
|
| 2014 |
Tanaka H, Yang GX, Iwakoshi N, Knechtle SJ, Kawata K, Tsuneyama K, Leung P, Coppel RL, Ansari AA, Joh T, Bowlus C, Gershwin ME. Anti-CD40 ligand monoclonal antibody delays the progression of murine autoimmune cholangitis. Clinical and Experimental Immunology. 174: 364-71. PMID 23981074 DOI: 10.1111/Cei.12193 |
0.324 |
|
| 2014 |
Yimam KK, Bowlus CL. Obeticholic acid for the treatment of primary biliary cirrhosis Expert Opinion On Orphan Drugs. 2: 1351-1358. DOI: 10.1517/21678707.2014.964206 |
0.373 |
|
| 2013 |
Liu JZ, Hov JR, Folseraas T, Ellinghaus E, Rushbrook SM, Doncheva NT, Andreassen OA, Weersma RK, Weismüller TJ, Eksteen B, Invernizzi P, Hirschfield GM, Gotthardt DN, Pares A, Ellinghaus D, ... ... Bowlus CL, et al. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nature Genetics. 45: 670-5. PMID 23603763 DOI: 10.1038/Ng.2616 |
0.349 |
|
| 2013 |
Pollheimer M, Bowlus C, Lackner C, Karlsen T, Hov J, Lyman S, Adamkewicz J, Mikels-Vigdal A, Marshall D, Smith V, Trauner M, Fickert P. 694 LYSYL OXIDASE-LIKE 2 (LOXL2) PROTEIN IS INDUCED IN HUMAN CHOLESTATIC LIVER DISEASE AND IN ANIMAL MODELS OF CHOLANGIOPATHIES Journal of Hepatology. 58: S281-S282. DOI: 10.1016/S0168-8278(13)60696-0 |
0.309 |
|
| 2012 |
Tanaka H, Leung PS, Kenny TP, Gershwin ME, Bowlus CL. Immunological orchestration of liver fibrosis. Clinical Reviews in Allergy & Immunology. 43: 220-9. PMID 22695942 DOI: 10.1007/S12016-012-8323-1 |
0.377 |
|
| 2012 |
Kawata K, Kobayashi Y, Gershwin ME, Bowlus CL. The immunophysiology and apoptosis of biliary epithelial cells: primary biliary cirrhosis and primary sclerosing cholangitis. Clinical Reviews in Allergy & Immunology. 43: 230-41. PMID 22689287 DOI: 10.1007/S12016-012-8324-0 |
0.369 |
|
| 2012 |
Gupta A, Bowlus CL. Primary sclerosing cholangitis: etiopathogenesis and clinical management. Frontiers in Bioscience (Elite Edition). 4: 1683-705. PMID 22201985 DOI: 10.2741/490 |
0.366 |
|
| 2012 |
Tsuda M, Moritoki Y, Lian ZX, Zhang W, Yoshida K, Wakabayashi K, Yang GX, Nakatani T, Vierling J, Lindor K, Gershwin ME, Bowlus CL. Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Hepatology (Baltimore, Md.). 55: 512-21. PMID 22006563 DOI: 10.1002/Hep.24748 |
0.331 |
|
| 2011 |
Medici V, Virata MC, Peerson JM, Stabler SP, French SW, Gregory JF, Albanese A, Bowlus CL, Devaraj S, Panacek EA, Richards JR, Halsted CH. S-adenosyl-L-methionine treatment for alcoholic liver disease: a double-blinded, randomized, placebo-controlled trial. Alcoholism, Clinical and Experimental Research. 35: 1960-5. PMID 22044287 DOI: 10.1111/J.1530-0277.2011.01547.X |
0.326 |
|
| 2011 |
Toy E, Balasubramanian S, Selmi C, Li CS, Bowlus CL. The prevalence, incidence and natural history of primary sclerosing cholangitis in an ethnically diverse population. Bmc Gastroenterology. 11: 83. PMID 21767410 DOI: 10.1186/1471-230X-11-83 |
0.304 |
|
| 2011 |
Zhang W, Ono Y, Miyamura Y, Bowlus CL, Gershwin ME, Maverakis E. T cell clonal expansions detected in patients with primary biliary cirrhosis express CX3CR1. Journal of Autoimmunity. 37: 71-8. PMID 21636249 DOI: 10.1016/J.Jaut.2011.05.009 |
0.349 |
|
| 2011 |
Selmi C, Bowlus CL, Gershwin ME, Coppel RL. Primary biliary cirrhosis. Lancet (London, England). 377: 1600-9. PMID 21529926 DOI: 10.1016/S0140-6736(10)61965-4 |
0.404 |
|
| 2011 |
Rong G, Zhong R, Lleo A, Leung PS, Bowlus CL, Yang GX, Yang CY, Coppel RL, Ansari AA, Cuebas DA, Worman HJ, Invernizzi P, Gores GJ, Norman G, He XS, et al. Epithelial cell specificity and apotope recognition by serum autoantibodies in primary biliary cirrhosis. Hepatology (Baltimore, Md.). 54: 196-203. PMID 21488079 DOI: 10.1002/Hep.24355 |
0.313 |
|
| 2011 |
Bowlus CL, Seeley EH, Roder J, Grigorieva J, Roder H, Caprioli RM, Gershwin M. In situ mass spectrometry of autoimmune liver diseases. Cellular & Molecular Immunology. 8: 237-42. PMID 21258365 DOI: 10.1038/Cmi.2010.72 |
0.346 |
|
| 2011 |
Bowlus CL. Cutting edge issues in primary sclerosing cholangitis. Clinical Reviews in Allergy & Immunology. 41: 139-50. PMID 21170605 DOI: 10.1007/S12016-010-8221-3 |
0.361 |
|
| 2010 |
Lleo A, Bowlus CL, Yang GX, Invernizzi P, Podda M, Van de Water J, Ansari AA, Coppel RL, Worman HJ, Gores GJ, Gershwin ME. Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. Hepatology (Baltimore, Md.). 52: 987-98. PMID 20568301 DOI: 10.1002/Hep.23783 |
0.358 |
|
| 2010 |
Medici V, Peerson JM, Stabler SP, French SW, Gregory JF, Virata MC, Albanese A, Bowlus CL, Devaraj S, Panacek EA, Rahim N, Richards JR, Rossaro L, Halsted CH. Impaired homocysteine transsulfuration is an indicator of alcoholic liver disease. Journal of Hepatology. 53: 551-7. PMID 20561703 DOI: 10.1016/J.Jhep.2010.03.029 |
0.322 |
|
| 2009 |
Borchers AT, Shimoda S, Bowlus C, Keen CL, Gershwin ME. Lymphocyte recruitment and homing to the liver in primary biliary cirrhosis and primary sclerosing cholangitis. Seminars in Immunopathology. 31: 309-22. PMID 19533132 DOI: 10.1007/S00281-009-0167-2 |
0.355 |
|
| 2009 |
Aron JH, Bowlus CL. The immunobiology of primary sclerosing cholangitis. Seminars in Immunopathology. 31: 383-97. PMID 19468733 DOI: 10.1007/S00281-009-0154-7 |
0.372 |
|
| 2009 |
Moritoki Y, Zhang W, Tsuneyama K, Yoshida K, Wakabayashi K, Yang GX, Bowlus C, Ridgway WM, Ueno Y, Ansari AA, Coppel RL, Mackay IR, Flavell RA, Gershwin ME, Lian ZX. B cells suppress the inflammatory response in a mouse model of primary biliary cirrhosis. Gastroenterology. 136: 1037-47. PMID 19118554 DOI: 10.1053/J.Gastro.2008.11.035 |
0.371 |
|
| 2008 |
Selmi C, Zuin M, Bowlus CL, Gershwin ME. Anti-mitochondrial antibody-negative primary biliary cirrhosis. Clinics in Liver Disease. 12: 173-85, ix. PMID 18242503 DOI: 10.1016/J.Cld.2007.11.008 |
0.316 |
|
| 2007 |
Selmi C, Bowlus CL, Keen CL, Gershwin ME. Non-alcoholic fatty liver disease: the new epidemic and the need for novel nutritional approaches. Journal of Medicinal Food. 10: 563-5. PMID 18158823 DOI: 10.1089/Jmf.2007.620 |
0.313 |
|
| 2007 |
Selmi C, Gershwin ME, Lindor KD, Worman HJ, Gold EB, Watnik M, Utts J, Invernizzi P, Kaplan MM, Vierling JM, Bowlus CL, Silveira MG, Bossi I. Quality of life and everyday activities in patients with primary biliary cirrhosis. Hepatology (Baltimore, Md.). 46: 1836-43. PMID 18027862 DOI: 10.1002/Hep.21953 |
0.307 |
|
| 2007 |
Medici V, Di Leo V, Lamboglia F, Bowlus CL, Tseng SC, D'Incà R, Irato P, Burra P, Martines D, Sturniolo GC. Effect of penicillamine and zinc on iron metabolism in Wilson's disease. Scandinavian Journal of Gastroenterology. 42: 1495-500. PMID 17994470 DOI: 10.1080/00365520701514495 |
0.314 |
|
| 2007 |
Buse JB, Klonoff DC, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Maggs DG, Wintle ME. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials Clinical Therapeutics. 29: 139-153. PMID 17379054 DOI: 10.1016/J.Clinthera.2007.01.015 |
0.308 |
|
| 2007 |
Seo S, Maganti K, Khehra M, Ramsamooj R, Tsodikov A, Bowlus C, McVicar J, Zern M, Torok N. De novo nonalcoholic fatty liver disease after liver transplantation. Liver Transplantation : Official Publication of the American Association For the Study of Liver Diseases and the International Liver Transplantation Society. 13: 844-7. PMID 17029282 DOI: 10.1002/Lt.20932 |
0.342 |
|
| 2006 |
Aoki CA, Dawson K, Kenny TP, Gershwin ME, Bowlus CL. Gene expression by PBMC in primary sclerosing cholangitis: evidence for dysregulation of immune mediated genes. Clinical & Developmental Immunology. 13: 265-71. PMID 17162367 DOI: 10.1080/17402520600800085 |
0.338 |
|
| 2006 |
Aoki CA, Roifman CM, Lian ZX, Bowlus CL, Norman GL, Shoenfeld Y, Mackay IR, Gershwin ME. IL-2 receptor alpha deficiency and features of primary biliary cirrhosis. Journal of Autoimmunity. 27: 50-3. PMID 16904870 DOI: 10.1016/J.Jaut.2006.04.005 |
0.308 |
|
| 2006 |
Lan RY, Cheng C, Lian ZX, Tsuneyama K, Yang GX, Moritoki Y, Chuang YH, Nakamura T, Saito S, Shimoda S, Tanaka A, Bowlus CL, Takano Y, Ansari AA, Coppel RL, et al. Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis. Hepatology (Baltimore, Md.). 43: 729-37. PMID 16557534 DOI: 10.1002/Hep.21123 |
0.348 |
|
| 2006 |
Ichiki Y, Bowlus CL, Shimoda S, Ishibashi H, Vierling JM, Gershwin ME. T cell immunity and graft-versus-host disease (GVHD). Autoimmunity Reviews. 5: 1-9. PMID 16338205 DOI: 10.1016/J.Autrev.2005.02.006 |
0.321 |
|
| 2005 |
Ichiki Y, Aoki CA, Bowlus CL, Shimoda S, Ishibashi H, Gershwin ME. T cell immunity in autoimmune hepatitis. Autoimmunity Reviews. 4: 315-21. PMID 15990080 DOI: 10.1016/J.Autrev.2005.01.005 |
0.318 |
|
| 2005 |
Aoki CA, Bowlus CL, Gershwin ME. The immunobiology of primary sclerosing cholangitis. Autoimmunity Reviews. 4: 137-43. PMID 15823499 DOI: 10.1016/J.Autrev.2004.09.003 |
0.324 |
|
| 2005 |
Bowlus CL, Willner I, Zern MA, Reuben A, Chen P, Holladay B, Xie L, Woolson RF, Strange C. Factors associated with advanced liver disease in adults with alpha1-antitrypsin deficiency. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. 3: 390-6. PMID 15822045 DOI: 10.1016/S1542-3565(05)00082-0 |
0.324 |
|
| 2005 |
Cheunsuk S, Lian ZX, Yang GX, Gershwin ME, Gruen JR, Bowlus CL. Prss16 is not required for T-cell development. Molecular and Cellular Biology. 25: 789-96. PMID 15632078 DOI: 10.1128/Mcb.25.2.789-796.2005 |
0.734 |
|
| 2004 |
Ichiki Y, Bowlus CL, Shimoda S, Ishibashi H, Vierling JM, Gershwin ME. T cell immunity and graft-versus-host disease Autoimmunity Reviews. DOI: 10.1016/S1568-9972(04)00189-2 |
0.323 |
|
| 2003 |
Lie BA, Akselsen HE, Bowlus CL, Gruen JR, Thorsby E, Undlien DE. Polymorphisms in the gene encoding thymus-specific serine protease in the extended HLA complex: a potential candidate gene for autoimmune and HLA-associated diseases. Genes and Immunity. 3: 306-12. PMID 12140752 DOI: 10.1038/Sj.Gene.6363858 |
0.324 |
|
| 2003 |
Aoki C, Rossaro L, Ramsamooj R, Bowlus CL. Hepcidin mRNA expression in human liver correlates with serum ferritin Gastroenterology. 124: A713. DOI: 10.1016/S0016-5085(03)83602-8 |
0.311 |
|
| 2003 |
Wu CT, Eiserich JP, Ansari AA, Coppel RL, Balasubramanian S, Bowlus C, Gershwin ME, Water JAVd. Myeloperoxidase-positive inflammatory cells participate in bile duct damage in primary biliary cirrhosis through nitric oxide-mediated reactions Hepatology. 38: 1018-1025. DOI: 10.1002/Hep.1840380428 |
0.37 |
|
| 2002 |
Cheunsuk S, Hsu T, Gershwin ME, Bowlus CL. Analysis of the IDDM candidate gene Prss16 in NOD and NON mice. Developmental Immunology. 9: 183-6. PMID 15144014 DOI: 10.1080/10446670310001593497 |
0.738 |
|
| 2002 |
Cheunsuk S, Sparks R, Noveroske JK, Hsu T, Justice MJ, Gershwin ME, Gruen JR, Bowlus CL. Expression, genomic structure and mapping of the thymus specific protease prss16: a candidate gene for insulin dependent diabetes mellitus susceptibility. Journal of Autoimmunity. 18: 311-6. PMID 12144812 DOI: 10.1006/Jaut.2002.0593 |
0.738 |
|
| 2001 |
Jain D, Bowlus CL, Anderson JM, Robert ME. Granular cells as a marker of early amiodarone hepatotoxicity. Journal of Clinical Gastroenterology. 31: 241-3. PMID 11034006 DOI: 10.1097/00004836-200010000-00012 |
0.301 |
|
| 1999 |
Bowlus CL, Ahn J, Chu T, Gruen JR. Cloning of a novel MHC-encoded serine peptidase highly expressed by cortical epithelial cells of the thymus. Cellular Immunology. 196: 80-6. PMID 10527559 DOI: 10.1006/Cimm.1999.1543 |
0.329 |
|
| Show low-probability matches. |